Phase 2b trial to test Haduvio as IPF chronic cough treatment
Trevi has launched a Phase 2b clinical trial to test Haduvio for the treatment of chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Trevi has launched a Phase 2b clinical trial to test Haduvio for the treatment of chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Enrollment is now complete in the CORAL clinical trial of nalbuphine ER, to be marketed as Haduvio, for IPF patients with chronic cough.| Pulmonary Fibrosis News
A Phase 2b clinical trial testing Haduvio for IPF cough reached 75% of targeted enrollment but is still recruiting patients in 10 countries.| Pulmonary Fibrosis News
In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.| Pulmonary Fibrosis News
